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CHAPTER 1
Serotonin–dopamine interaction: an overview
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Abstract: Central serotonergic and dopaminergic systems play a critical role in the regulation of normal
and abnormal behaviours. Moreover, recent evidence suggests that the dysfunction of dopamine (DA) and
serotonin (5-hydroxytriptamine, 5-HT) neurotransmission might underlie the pathophysiology of
neuropsychiatric disorders, including depression, schizophrenia, attention deﬁcit hyperactivity disorders,
drug abuse, Gilles de la Tourette’s syndrome and Parkinson’s disease.
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The interaction between the two amines in the
brain, in normal and pathological conditions, is an
intriguing research ﬁeld and a better understand-
ing will provide new pharmacological approaches
for the treatment of several neuropsychiatric
disorders. An extensive scientiﬁc literature has
investigated the role of serotonin (5-hydroxytrip-
tamine, 5-HT) in the control of central dopamine
(DA) systems, and their dysfunction in pathologi-
cal conditions. In neuropsychiatric disorders, the
involvement of 5-HT and DA has been indicated
and singled out and new therapeutic approaches
suggested. Nevertheless, the interaction between
5-HT and DA systems is far from being completely
revealed.
The interaction between 5-HT and DA in the
brain is a research topic that has raised the interest
of many scientists working in the ﬁeld of
neuroscience since the ﬁrst demonstration of the
presence of monoamine-containing neurons in the
mid-1960s. Thus, a seminal work by Fuxe (1965)
reported the presence of 5-HT-containing termi-
nals in both the substantia nigra (SN) and the
ventral tegmental area (VTA). It was subsequently
found that serotonergic nerve terminals originat-
ing from the dorsal raphe nucleus (DRN) inner-
vated both the SN and the VTA (Steinbusch,
1981), whereas 5-HT ﬁbres arising from median
raphe nucleus (MNR) innervated the VTA but not
the SN (Fibiger and Miller, 1977; Azmitia and
Segal, 1978). Based on those anatomical studies,
several investigators began to study the beha-
vioural, biochemical and electrophysiological rele-
vance of the neuroanatomical ﬁndings. Further
impetus was given to this research by the increas-
ing evidence that most psychotropic drugs, includ-
ing antidepressants, antipsychotics, opioids,
anxiolytics and psychostimulants, exerted their
pharmacological actions by interfering with sero-
tonergic and dopaminergic transmission. An
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almost parallel and concomitant progress was
made in the identiﬁcation, characterization and
cloning of 5-HT receptor subtypes (Boess and
Martin, 1994).
Early studies showed that experimental manipu-
lations aimed at decreasing central 5-HT function,
such as selective nerve lesions by neurotoxin,
inhibition of 5-HT synthesis or 5-HT receptor
blockade, tended to potentiate the behavioural and
neurochemical effects of drugs such as ampheta-
mine and related compounds, enhancing the
dopaminergic transmission, thus leading to the
conclusion that central serotonergic systems inhi-
bit DA functions (Samanin and Garattini, 1975).
The interest of our laboratory in investigating
5-HT/DA interaction sprang from these early
studies. Our approach was based on in vivo
electrophysiological and neurochemical techniques.
The experimental data gathered over a period of
almost 20 years lead to the conclusion that several
5-HT receptor subtypes, including the 5-HT1A,
5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act
to facilitate neuronal DA function and release,
while the 5-HT2C receptor mediates an inhibitory
effect of 5-HT on the basal electrical activity of
dopaminergic neurons and on DA release.
A detailed analysis and discussion of the above-
mentioned data are reported in this book. Of
particular interest is the ﬁnding that 5-HT2A and
5-HT2C receptors exert opposite actions on dopa-
minergic activity, although they belong to the same
receptor family, and share almost identical cellular
transduction mechanisms. One possible mechani-
sm of this opposite action is the intermediation of
a g-aminobutyric acid (GABA)-ergic neuron in the
inhibitory effect of 5-HT2C receptors on DA
function. Based on this hypothesis, 5-HT2A
receptor stimulation would cause a direct excita-
tion of DA-containing neurons, whereas activation
of 5-HT2C receptors would indirectly inhibit these
neurons by stimulating a GABA-containing inter-
neuron (Di Giovanni et al., 2001; Di Matteo et al.,
2001). However, although early neuroanatomical
data showing that 5-HT2C receptors are
restricted to GABA-containing neurons in the
SN (Eberle-Wang et al., 1997) strengthened this
hypothesis, it was recently found that in the VTA,
5-HT2C receptor protein is expressed on both DA
and GABA-containing neurons (Bubar and
Cunningham, 2007). Thus, there are several
possible anatomical sites of 5-HT/DA interaction:
it may be at the level of brainstem where SN
and VTA are located, and/or at the level of
projection areas of nigrostriatal and mesocortico-
limbic dopaminergic systems, including the stria-
tum, the nucleus accumbens and the prefrontal
cortex. The interaction might be either direct
(i.e. mediated by 5-HT receptors located on the
cell body and/or on nerve terminals of DA
neurons) or indirect (i.e. by 5-HT receptors located
on interneurons impinging on DA neurons and/or
by short or long feed-back loops originating from
innervated brain areas).
It is interesting to note that a number of
behavioural studies are consistent with electro-
physiological and neurochemical ﬁndings, in that
5-HT2C receptor antagonists were found to
potentiate the effects of several psychostimulant
drugs including cocaine, nicotine and ampheta-
mine-like compounds, whereas 5-HT2A receptor
antagonists had the opposite effect (Bubar and
Cunningham, 2008). Moreover, 5-HT2C receptor
agonists reduce the locomotor and rewarding
effects of several drugs of abuse, including
nicotine, ethanol, cocaine and amphetamine-like
drugs. It is noteworthy that the locomotor and
rewarding effects of cocaine were clearly poten-
tiated in 5-HT2C receptor null mutant mice (Rocha
et al., 2002). Therefore, an important aspect of
5-HT/DA interaction relates to the possibility
of using 5-HT2C receptor agonists in the therapy
of addictive disorders. In this respect, it is
important to note that several new selective and
potent 5-HT2C receptor agonists have been deve-
loped, which might be useful to treat disturbances
of consummatory behaviours such as overeating
and drug addiction, which are now considered
related disorders. An intriguing aspect of this
problem is the recent ﬁnding that the tumour
suppressor enzyme PTEN (phosphatase and tensin
homologue deleted on chromosome 10) directly
interacts with a region in the third intracellular
loop (3L4F) of 5-HT2C receptors in the rat VTA.
PTEN limits agonist-induced 5-HT2C receptor
phosphorylation via its protein phosphatase
activity. Systemic or intra-VTA application of the
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interfering peptide Tat-3L4F is capable of disrupt-
ing PTEN coupling with 5-HT2C in the rat VTA,
resulting both in a suppression of the increased
ﬁring rate of VTA dopaminergic neurons induced
by D9-tetrahydrocannabinol (THC), the psycho-
active ingredient of marijuana, and in a blockade
of the conditioned place preference induced by
THC and nicotine (Ji et al., 2006). This represents
a very good example of integration of classical
pharmacology with up-to-date molecular biology
techniques.
Another important characteristic of the 5-HT2C
receptor subtype is that it undergoes post-
transcriptional editing. Thus, the 5-HT2C receptor
is the only seven transmembrane domain receptor
to date found to undergo the post-transcriptional
process of mRNA editing, which generates unique
isoforms of proteins in a cell- and/or tissue-speciﬁc
manner. mRNA transcripts of the rat and human
5-HT2C receptor undergo adenosine-to-inosine
editing events at ﬁve sites which encompass amino
acids 156–160 within the putative second intracel-
lular domain of the encoded human receptor,
resulting in the production of fourteen 5-HT2C
receptor isoforms (Berg et al., 2005). There is
increasing evidence that some of these isoforms
might be linked to a higher probability of
developing depression and psychosis.
The chapters of this book are devoted to the
analysis of the relevance of 5-HT/DA interaction
in learning and memory, the sleep/wake cycle,
attention and impulsivity, and the pathophysio-
logy of several neuropsychiatric disorders, includ-
ing depression, schizophrenia and other psychotic
disorders, drug abuse, Gilles de la Tourette’s
syndrome, attention deﬁcit hyperactivity disorders
(ADHD), Parkinson’s disease, Alzheimer’s dis-
ease, diskynesias and motor tics. The detailed
knowledge of 5-HT/DA interaction would also
help in understanding the mechanism of action of
most psychotropic drugs, including antidepres-
sant, antipsychotic and anti-addictive drugs that is
thought to be mediated, at least in part, via the
5-HT system. 5-HT research is now more than 50
years old, and it has generated a wealth of
therapeutic agents, some of which have had a
major impact on disease management. Not sur-
prisingly, 5-HT receptors and transporters
continue to be a major focus of CNS drug
discovery. In fact, of the top CNS drugs by total
sales, most modulate 5-HT neurotransmission
(Segest, 2007). Furthermore, the selective 5-HT
reuptake inhibitors (SSRIs) are among the most
widely prescribed drugs for treating depression
and a variety of other disorders including anxiety
and social phobia. But we are a long way from a
serotoninergic therapeutic intervention for other
neuropsychiatric diseases.
5-HT receptor research has generated detailed
information on the molecular biology and regional
and cellular localization of these receptors.
A major challenge now is to utilize this knowledge
to develop receptor-speciﬁc drugs and use the
information gained to better treat central nervous
system disorders. In addition, further clariﬁcation
of the role of 5-HT transmission in the pathophy-
siology of neuropsychiatric disorders is required,
since the overall picture is still confusing. It is
likely that 5-HT2C ligands are promising candi-
dates (Di Giovanni et al., 2006; Rosenzweig-
Lipson et al., 2007). Moreover, there are also
many avenues that remain unexplored, so there are
undoubtedly further advances to be made. The
intensive research in medicinal chemistry will help
this ﬁeld of investigation. In fact, more selective
ligands for 5-HT receptors are currently produced.
In the future, the use of such selective ligands,
especially agonists of 5-HT receptors, would
certainly be helpful in determining their functional
importance and their involvement in the patho-
genesis of diseases, not exclusively of the
CNS. This has a particular relevance for those
disorders such as Parkinsons’s disease that are still
fatal and for which at present there is no cure
(Esposito et al., 2007; Di Giovanni, 2008). How-
ever, it should be kept in mind that although
selective receptor ligands are an important and
indispensable research tool, they rarely happen, in
practice, to be drugs. Many questions need to be
answered before we can truly understand how
these 5-HT receptors regulate DA neuronal
activity in the brain. The challenge ahead is to
build on this foundation and keep up this
engaging adventure: the interaction between
5-HT and DA systems is far from being completely
revealed.
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